AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 163 filers reported holding AGIOS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 1.81 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,174,661 | -79.6% | 47,461 | -81.1% | 0.00% | -66.7% |
| Q2 2023 | $5,754,767 | 0.0% | 250,534 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $5,754,767 | -49.7% | 250,534 | -38.5% | 0.00% | -50.0% |
| Q4 2022 | $11,437,237 | -99.9% | 407,309 | -11.3% | 0.01% | -14.3% |
| Q3 2022 | $12,990,278,000 | +23.1% | 459,345 | -3.5% | 0.01% | +16.7% |
| Q2 2022 | $10,553,210,000 | +460.3% | 476,013 | +635.7% | 0.01% | +500.0% |
| Q1 2022 | $1,883,446,000 | -11.4% | 64,701 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $2,126,723,000 | -30.4% | 64,701 | -2.3% | 0.00% | 0.0% |
| Q3 2021 | $3,056,377,000 | -23.3% | 66,227 | -8.4% | 0.00% | -50.0% |
| Q2 2021 | $3,984,123,000 | -19.1% | 72,294 | -24.2% | 0.00% | 0.0% |
| Q1 2021 | $4,923,098,000 | +24.0% | 95,335 | +4.1% | 0.00% | 0.0% |
| Q4 2020 | $3,969,722,000 | +48.3% | 91,616 | +19.8% | 0.00% | +100.0% |
| Q3 2020 | $2,677,325,000 | -35.9% | 76,495 | -2.1% | 0.00% | -66.7% |
| Q2 2020 | $4,177,859,000 | -73.8% | 78,120 | -82.6% | 0.00% | -72.7% |
| Q1 2020 | $15,959,861,000 | -30.3% | 449,827 | -6.3% | 0.01% | -21.4% |
| Q4 2019 | $22,914,367,000 | +80.1% | 479,882 | +22.2% | 0.01% | +55.6% |
| Q3 2019 | $12,720,888,000 | -33.5% | 392,620 | +2.3% | 0.01% | -35.7% |
| Q2 2019 | $19,141,350,000 | -1.8% | 383,748 | +32.7% | 0.01% | 0.0% |
| Q1 2019 | $19,496,498,000 | +44.4% | 289,094 | -1.3% | 0.01% | +16.7% |
| Q4 2018 | $13,505,803,000 | -27.2% | 292,904 | +21.8% | 0.01% | -14.3% |
| Q3 2018 | $18,541,037,000 | -21.6% | 240,418 | -14.4% | 0.01% | -22.2% |
| Q2 2018 | $23,661,049,000 | -10.9% | 280,910 | -13.5% | 0.02% | -14.3% |
| Q1 2018 | $26,558,218,000 | +34.5% | 324,752 | -5.9% | 0.02% | +23.5% |
| Q4 2017 | $19,739,887,000 | +812.6% | 345,284 | +965.5% | 0.02% | +750.0% |
| Q3 2017 | $2,163,100,000 | +55.2% | 32,406 | +19.6% | 0.00% | +100.0% |
| Q2 2017 | $1,393,677,000 | -9.0% | 27,088 | +3.2% | 0.00% | -50.0% |
| Q1 2017 | $1,532,182,000 | +264069.3% | 26,236 | +88.9% | 0.00% | +100.0% |
| Q4 2016 | $580,000 | -55.9% | 13,891 | -44.2% | 0.00% | 0.0% |
| Q3 2016 | $1,315,000 | -84.3% | 24,899 | -87.5% | 0.00% | -88.9% |
| Q2 2016 | $8,362,000 | +2.0% | 199,602 | -1.1% | 0.01% | -10.0% |
| Q1 2016 | $8,195,000 | -36.0% | 201,846 | +2.3% | 0.01% | -33.3% |
| Q4 2015 | $12,807,000 | -11.4% | 197,267 | -3.7% | 0.02% | -6.2% |
| Q3 2015 | $14,458,000 | -37.2% | 204,814 | -1.2% | 0.02% | -27.3% |
| Q2 2015 | $23,040,000 | +21.0% | 207,313 | +2.7% | 0.02% | +22.2% |
| Q1 2015 | $19,037,000 | +3.3% | 201,880 | +22.7% | 0.02% | 0.0% |
| Q4 2014 | $18,431,000 | +118.0% | 164,500 | +19.4% | 0.02% | +125.0% |
| Q3 2014 | $8,454,000 | +224.4% | 137,800 | +26.7% | 0.01% | +166.7% |
| Q4 2013 | $2,606,000 | +43.6% | 108,800 | +67.6% | 0.00% | +50.0% |
| Q3 2013 | $1,815,000 | – | 64,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |